Rock Springs Capital Management LP Acquires Shares of 26,757 Dianthus Therapeutics, Inc. $DNTH

Rock Springs Capital Management LP acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 26,757 shares of the company’s stock, valued at approximately $2,245,000.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the first quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at about $40,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC boosted its stake in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at $2,424,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,779 shares of company stock valued at $7,985,235 in the last quarter. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $104.49 on Tuesday. The business’s 50 day simple moving average is $91.14 and its two-hundred day simple moving average is $76.70. The stock has a market capitalization of $5.71 billion, a P/E ratio of -25.30 and a beta of 1.20. Dianthus Therapeutics, Inc. has a one year low of $18.08 and a one year high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on DNTH shares. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.